Bradykinin
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Bradykinin?
Summarize this article for a 10 year old
Bradykinin (BK) (Greek brady-, slow; -kinin, kīn(eîn) to move) is a peptide that promotes inflammation. It causes arterioles to dilate (enlarge) via the release of prostacyclin, nitric oxide, and endothelium-derived hyperpolarizing factor and makes veins constrict, via prostaglandin F2, thereby leading to leakage into capillary beds, due to the increased pressure in the capillaries. Bradykinin consists of nine amino acids, and is a physiologically and pharmacologically active peptide of the kinin group of proteins.
Names | |
---|---|
IUPAC name
Bradykinin | |
Systematic IUPAC name
(2S)-2-{(12S,32S,9S,12S,142S,17S)-11-[(2S)-2-Amino-5-(carbamimidoylamino)pentanoyl]-9-benzyl-12-(hydroxymethyl)-2,4,7,10,13,15-hexaoxo-5,8,11,16-tetraaza-1(2),3,14(1,2)-tripyrrolidina-19-benzenanonadecaphane-17-carboxamido}-5-(carbamimidoylamino)pentanoic acid | |
Identifiers | |
| |
3D model (JSmol) |
|
ChEBI | |
ChEMBL | |
ChemSpider |
|
ECHA InfoCard | 100.000.362 |
MeSH | Bradykinin |
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C50H73N15O11 | |
Molar mass | 1060.228 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
kininogen 1 | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
Symbol | KNG1 | ||||||
Alt. symbols | KNG, BDK | ||||||
NCBI gene | 3827 | ||||||
HGNC | 6383 | ||||||
OMIM | 612358 | ||||||
RefSeq | NM_001102416 | ||||||
UniProt | P01042 | ||||||
Other data | |||||||
Locus | Chr. 3 q21-qter | ||||||
|
Bradykinin | |||||||||
---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||
Symbol | Bradykinin | ||||||||
Pfam | PF06753 | ||||||||
InterPro | IPR009608 | ||||||||
|
A class of drugs called angiotensin-converting-enzyme inhibitors (ACE inhibitors) increase bradykinin levels by inhibiting its degradation, thereby increasing its blood pressure lowering effect. ACE inhibitors are FDA approved for the treatment of hypertension and heart failure.